Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (3) | Back to Search
CLINICAL IMPLICATIONS OF NIVOLUMAB IN CANCER IMMUNOTHERAPY
- In: Poster Session
- At: Düsseldorf (Germany) (2015)
- Type: Poster
- By: KUCUK, Esra (Hacettepe University Faculty of Pharmacy, Clinical Pharmacy, Ankara, Turkey)
- Co-author(s): Esra KUCUK
Ecz. Burcu Kelleci, Hacettepe Universitesi Eczacilik Fakultesi Klinik Eczacilik Anabilim Dali - Abstract:
A cancer treatment recently focuses on immunotherapy such as nivolumab, ipilimumab and pembrolizumab.
We searched through the Pub-Med database (between 2010-2015) by using nivolumab and immunotherapy as keywords.
Nivolumab is administered via iv infusion over an hour at the dose of 2-3mg/kg for every 2-3 weeks. Drug must be constituted with 0,9%
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023